Incyte CorporationNasdaq: INCY
Health Care · Biotechnology
$96.87
+1.68%
Vol: 852K
Research Digest
Friday, May 1, 2026
Incyte beats Q1 estimates with 35% EPS upside and European regulatory approval for dermatology asset
Q1 2026 EPS of $1.81 beat estimate by 35% with $1.27B revenue (4.66% beat) on margin expansion despite sequential decline. European Commission approved Zynyz for first-line anal squamous cell carcinoma. Povorcitinib showed positive 54-week data for Hidradenitis Suppurativa; Tafasitamab Phase 3 data positive at ASCO. Four new product launches expected next year.
Previous Market Intelligence
13 daysApr 30Incyte delivered strong Q1 2026 with $1.27B revenue (21% YoY growth) and $1.81 EPS, crushing estimates by 35%, and appointed new Chief Medical Officer.Positive▶
Incyte Corporation reported Q1 2026 with total revenue of $1.27 billion, representing 21% year-over-year increase and exceeding estimates by 4.7%. Diluted EPS of $1.81 beat estimates by 35%. The company appointed Pablo Cagnoni as President and Global Head of R&D and Steven Stein as Chief Medical Officer and Head of Late-stage Development. Incyte is transitioning beyond single-product dependency toward diversified portfolio across hematology, oncology, and immunology. Four new product launches expected in next year. However, full-year guidance missed analyst expectations.
Apr 29Incyte Q1 2026 net sales hit $1.104B (+20% YoY), beating consensus with EPS $1.81 vs $1.35 estimate; Stifel raises PT to $123Positive▶
Incyte Corporation reported Q1 2026 total net sales of $1.104 billion, up 20% YoY, with EPS of $1.81 significantly above $1.35 consensus. Jakafi net sales reached $758M, up 7% YoY. Positive CHMP opinion for Zynyz (retifanlimab) for first-line advanced squamous cell carcinoma announced. Povorcitinib NDA acceptance in hidradenitis suppurativa and Phase 3 positives in vitiligo. 10 Phase 3 studies underway including INCB161734 in pancreatic adenocarcinoma. Stifel raised price target to $123 from $120 maintaining Buy. Multiple catalysts expected through year-end 2026.
Apr 16Incyte reported positive 54-week data for Povorcitinib in Hidradenitis Suppurativa and plans Q1 2026 earnings report on April 28, 2026.Positive▶
Incyte announced positive 54-week late-breaking data for experimental skin disease drug Povorcitinib in Hidradenitis Suppurativa at AAD Annual Meeting March 28, 2026. Company expects 36% EPS increase to $1.21 in Q1 2026 with trailing twelve-month EPS of $6.79 showing 414% year-over-year growth. Q1 2026 earnings report scheduled for April 28, 2026. Incyte highlighted potential for four launches, four pivotal trial readouts, seven proof-of-concept readouts, and three Phase 3 study initiations. Beacon Harbor Wealth Advisors acquired 68,069 shares valued at approximately $6.7 million in Q4 2025. Stock at $97.69 after 2.24% daily gain; up 69.95% over past year.
Apr 15Incyte to report Q1 2026 results on April 28; RBC Capital raised price target to $95; new clinical collaboration announced.Positive▶
Incyte will report Q1 2026 results on April 28. RBC Capital raised price target to $95 from $92 on April 7. Adagene announced a clinical collaboration with Incyte for combination therapies. Incyte Japan received approval of Zynyz for first-line treatment of advanced anal cancer. Consensus analyst rating is Buy with $100.21 price target.
Apr 14Incyte Q1 2026 earnings due April 28; Weiss Ratings upgraded to Buy on April 1.Positive▶
Incyte scheduled Q1 2026 financial results for April 28 at 7:00 a.m. ET. Weiss Ratings upgraded from Hold to Buy April 1. Focused on expanding oncology/immunology pipeline with positive povorcitinib data. RBC Capital raised target to $95 from $92 with Sector Perform. Adagene announced clinical collaboration.
Apr 13Incyte scheduled Q1 2026 earnings April 28 with positive povorcitinib drug data; RBC raised price target to $95 from $92.Positive▶
Incyte Q1 2026 earnings conference call set for April 28. Company preparing to report following positive data for povorcitinib. RBC Capital raised price target to $95 from $92. Multiple institutional investors increased positions recently. Consensus Buy from 21 analysts with PT $100.21. Stock showed 65.75% one-year gain.
Apr 10Incyte Major Leadership Restructuring; Q1 Earnings April 28Neutral▶
Pablo Cagnoni appointed president/R&D head. Steven Stein as CMO. Mohamed Issa as U.S. commercial head. RBC raised target to $95.
Apr 9Incyte Q4 revenue beats; povorcitinib Phase 3 data strong, stock poised for 2026 growthMixed▶
Incyte reported Q4 2025 revenue $1.51B (+11.85% vs forecast) but EPS $1.80 missed -5.76%, causing 4.9% pre-market decline. FY2025 revenue grew 21% YoY to $5.14B; net sales up 20% to $4.35B. 2026 guidance projects 10-13% revenue growth; Opzelura sales $750-790M; Jakafi XR launch mid-2026. 54-week povorcitinib Phase 3 data for hidradenitis suppurativa presented at AAD. European Commission approved Zynyz for squamous cell carcinoma anal. Consensus "Buy" at $107.14 target per 11 analysts.
Apr 8Incyte stock rose 6.2% on promising povorcitinib Phase 3 data; STOP-HS results showed durable efficacy.Positive▶
INCY reported 54-week Phase 3 STOP-HS data for povorcitinib showing durable efficacy. Stock +6.2%. Guggenheim and Stifel Buy. Q1 earnings April 28.
Apr 7Incyte Reports Positive Povorcitinib Data, Multiple Regulatory Approvals Drive Stock MomentumPositive▶
Incyte announced promising 54-week late-breaking data for povorcitinib in hidradenitis suppurativa at AAD 2026. European Commission approved Minjuvi for relapsed/refractory follicular lymphoma and Zynyz for first-line anal cancer treatment. Q4 2025 earnings showed $1.80 EPS (beat $1.35) with $1.51B revenue. Stock up 6.2% on povorcitinib data. 21 analysts rate Buy with $100.21 mean target.
Apr 6Incyte Q4 revenue jumps 28% to $1.51B, Povorcitinib shows positive hidradenitis suppurativa dataPositive▶
Incyte Corporation reported Q4 2025 revenue growth of 28% to $1.51 billion, with full-year sales reaching $5.14 billion. Flagship product Jakafi achieved $3.093 billion in annual sales, while Opzelura expanded rapidly in atopic dermatitis and vitiligo markets. On March 28, 2026, Incyte announced positive 54-week late-breaking data for Povorcitinib in hidradenitis suppurativa at the AAD Annual Meeting. The European Commission approved Zynyz (retifanlimab) for first-line treatment of advanced squamous cell carcinoma of the anal canal. Executive leadership changes were announced March 25, 2026. According to 21 analysts, the average rating is Buy with a 12-month price target of $100.21, only 0.16% above current levels.
Apr 3Incyte reports Q4 2025 revenue of $1.51B (+28% YoY) driven by Jakafi and Opzelura expansion, announces $2B stock buyback program.Positive▶
Incyte reported Q4 2025 revenue of $1.51 billion, up 28% YoY, with full-year sales reaching $5.14 billion. Jakafi generated $3.093 billion annual sales. Announced positive Phase 2 results for Povorcitinib in Hidradenitis Suppurativa. Announced $2 billion share buyback program. Stock up 46.71% over past year. Consensus Buy with $100.21 target.
Apr 2Incyte reports positive 54-week Povorcitinib data for Hidradenitis Suppurativa; pipeline advancingPositive▶
Incyte Corporation announced positive 54-week late-breaking data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting on March 28, 2026. The company reported Q4 2025 revenue of $1.51 billion, up 28% year-over-year, with flagship Jakafi generating $3.093 billion in annual sales. Incyte also announced leadership appointments and a positive CHMP opinion for Zynyz for first-line treatment of squamous cell carcinoma. Stock closed at $90.30 on April 2, down 2.12% in 24 hours. Buy consensus with $100.21 price target.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| INCYINCYTE | $96.87 | +1.68% | +0.4% | 10.5x | 0.86 | $19.0B |
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| AMGNAMGEN | $330.27 | -4.62% | +1.1% | 14.8x | 0.47 | $186.7B |
| GILDGILEAD | $131.80 | +0.73% | -6.6% | 13.6x | 0.40 | $162.4B |
| VRTXVERTEX | $425.02 | -0.55% | -1.6% | 19.6x | 0.37 | $108.7B |
| REGNREGENERON | $702.19 | -0.69% | -7.3% | 13.0x | 0.40 | $74.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.